Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223594 · ClinicalTrials.gov registry record
Evaluation of Intravenous Fluid Therapy Within Dallas Acute Pancreatitis Protocol
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 500
- Enrollment target
NCT06223594: Completed study, sponsored by Methodist Health System.
NCT06223594 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06223594 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
Acute pancreatitis (AP) is a common disease of the gastrointestinal tract that can result in emotional, physical, and financial burdens on the patient.
Primary Outcome
Rate of fluid overload at 72 hours, which is the absence of acute respiratory distress syndrome.
Interventions
- OTHER Intravenous Fluid Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2025-07-22 |
What the finished NCT06223594 record still lists
NCT06223594 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Intravenous Fluid Therapy is the first listed.
NCT06223594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06223594 about?
NCT06223594 is a clinical study titled "Evaluation of Intravenous Fluid Therapy Within Dallas Acute Pancreatitis Protocol". Acute pancreatitis (AP) is a common disease of the gastrointestinal tract that can result in emotional, physical, and financial burdens on the patient.
What is the current status of trial NCT06223594?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2023-07-17. Estimated completion is 2025-07-22.
What interventions are being tested in trial NCT06223594?
The interventions under investigation include: Intravenous Fluid Therapy (OTHER).
Who is sponsoring clinical trial NCT06223594?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI